Cabenuva (Cabotegravir/Rilpivirine) for HIV | myHIVteam

Connect with others who understand.

sign up Log in
About myHIVteam
Powered By

Cabenuva is a combination prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with HIV-1 infection. Cabenuva is indicated as a complete treatment regimen. Cabenuva is used as a therapy for HIV-1 infection. Cabenuva is a combination of two drugs, cabotegravir and rilpivirine, that work together to prevent the HIV-1 virus from replicating inside body cells. Cabenuva is believed to work by interfering with viral DNA replication.

How do I take it?
Prescribing information states that Cabenuva is given as intramuscular injection by a health care professional.

Cabenuva is usually given in a health clinic or doctor’s office. It should be administered according to the frequency specified by your doctor. Cabenuva is available only as an intramuscular injection.

Side effects
The FDA-approved label for Cabenuva lists common side effects that include injection site reactions; fever; fatigue; headache; pain in the muscles, bones, ligaments, tendons, or nerves; nausea; sleep disorders; dizziness; and rash. Serious side effects listed for Cabenuva include hypersensitivity reactions, serious post-injection reactions, liver damage, and symptoms of depression.

For more details about this treatment, visit:

Cabenuva – ViiV Healthcare

FDA Approves First Extended-Release, Injectable Drug Regimen for Adults Living with HIV – U.S. Food and Drug Administration

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in